B cell-targeted therapies in Sjögren's syndrome
| Autor: | Pierre Youinou, Alain Saraux, Gabriel J. Tobón, Jacques-Olivier Pers |
|---|---|
| Přispěvatelé: | Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Laboratoire d'Immunologie et Immunothérapie, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Michel, Geneviève |
| Rok vydání: | 2010 |
| Předmět: |
MESH: Immunotherapy
Sialic Acid Binding Ig-like Lectin 2 medicine.medical_treatment MESH: Antigens CD20 Lymphocyte Activation Protein Engineering MESH: Antibodies Monoclonal 0302 clinical medicine B-Cell Activating Factor Immunology and Allergy Randomized Controlled Trials as Topic CD20 B-Lymphocytes 0303 health sciences education.field_of_study biology CD22 Antibodies Monoclonal Cell Differentiation 3. Good health MESH: Protein Engineering Sjogren's Syndrome medicine.anatomical_structure Cytokine MESH: Sialic Acid Binding Ig-like Lectin 2 [SDV.IMM]Life Sciences [q-bio]/Immunology Rituximab Immunotherapy medicine.drug MESH: Cell Differentiation [SDV.IMM] Life Sciences [q-bio]/Immunology Recombinant Fusion Proteins Immunology Population Lymphocyte Depletion 03 medical and health sciences Antigen MESH: B-Lymphocytes MESH: Cell Proliferation MESH: Recombinant Fusion Proteins medicine Humans MESH: B-Cell Activating Factor MESH: Lymphocyte Activation B-cell activating factor education B cell Cell Proliferation 030304 developmental biology MESH: Lymphocyte Depletion 030203 arthritis & rheumatology MESH: Humans business.industry Antigens CD20 MESH: Randomized Controlled Trials as Topic MESH: Sjogren's Syndrome biology.protein business |
| Zdroj: | Autoimmunity Reviews Autoimmunity Reviews, Elsevier, 2010, 9 (4), pp.224-8 |
| ISSN: | 1568-9972 |
| DOI: | 10.1016/j.autrev.2009.08.001 |
| Popis: | International audience; Sjögren's syndrome (SS) or autoimmune epithelitis is characterized by focal lymphocytic infiltrates surrounding the tubular epithelium of exocrine glands and by overactivity of the B-cell population. Although T cells were long considered the main effectors in SS, recent findings indicating a key role for B cells have prompted studies of treatments designed to deplete the B-cell population. Among molecules that can be targeted to achieve B-cell depletion, CD20 and CD22 are surface antigens expressed specifically by B lymphocytes; and the cytokine B-cell-activating factor belonging to the TNF family (BAFF) is a TNF receptor ligand involved in B-cell differentiation, survival, and activation. The aim of this review is to discuss the clinical outcomes of SS patients treated with B-cell depletion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect